+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A), By Treatment Type (On-demand), By Therapy (Gene Therapy & Monoclonal Antibodies), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 105 Pages
  • July 2023
  • Region: Global
  • Grand View Research
  • ID: 3822888
Description Jump to:
The global hemophilia market size is expected to reach USD 21.07 billion by 2030, expanding at a CAGR of 6.6% from 2023 to 2030. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin’s Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin’s Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights

  • The type A segment held the largest share of the hemophilia market owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy
  • Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2022, attributable to the specialized nature of the treatment required for the condition
  • By therapy factor replacement therapy held the largest share of the hemophilia market in 2022, as it is the major form of treatment used in both prophylaxis and on-demand treatment
  • North America was the largest revenue-generating region in the hemophilia market in 2022, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 The Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Hemophilia Market Variables, Trends, & Scope
4.1 Hemophilia Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration And Growth Prospect Mapping
4.3 Market Driver Analysis
4.3.1 Increasing Population Of Newborns
4.3.2 Favorable Government Initiatives
4.3.3 Rising R&D And New Product Development
4.3.4 Rising Adoption Of Prophylaxis Treatment
4.4 Market Restraint Analysis
4.4.1 High Cost Associated With Procuring Treatment
4.5 Porter’s Five Forces Analysis
4.6 Pestle Analysis
4.7 Pipeline Analysis
Chapter 5 Hemophilia Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)
5.1 Global Hemophilia Market: Type Movement Analysis
5.2. Hemophilia A5.2.1. Hemophilia A Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.3. Hemophilia B
5.3.1. Hemophilia B Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4. Others
5.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Hemophilia Market- Segment Analysis, By Treatment Type, 2018 - 2030 (USD Million)
6.1 Global Hemophilia Market: Treatment Type Movement Analysis
6.2. Prophylaxis
6.2.1. Prophylaxis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3. On-Demand
6.3.1. On-Demand Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4. Cure
6.4.1. Cure Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Hemophilia Market - Segment Analysis, By Therapy, 2018 - 2030 (USD Million)
7.1 Global Hemophilia Market: Therapy Movement Analysis
7.2. Factor Replacement Therapy
7.2.1. Factor Replacement Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.1 Plasma Derived Factor Concentrates
7.2.1.1.1 Plasma Derived Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.1.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.1.3 Factor Ix Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.2 Recombinant Factor Concentrates
7.2.1.2.1 Recombinant Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.2.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.2.3 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.2.1.2.4 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3. Gene Therapy & Monoclonal Antibodies
7.3.1. Gene Therapy & Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4. Desmopressin & Fibrin Sealants
7.4.1 Desmopressin & Fibrin Sealants Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Hemophilia Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
8.1 Global Hemophilia Market: Distribution Channel Movement Analysis
8.2. Hospital Pharmacies
8.2.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3. Specialty Pharmacies
8.3.1. Specialty Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9 Hemophilia Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)
9.1 Hemophilia Market: Regional Outlook
9.2 North America
9.2.1 North America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.2.3 Target Disease Prevalence
9.2.2.4 Competitive Scenario
9.2.2.5 Regulatory Framework
9.2.2.6 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.2.3.3 Target Disease Prevalence
9.2.3.4 Competitive Scenario
9.2.3.5 Regulatory Framework
9.2.3.6 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.3.2 UK
9.3.2.1 Key Country Dynamics
9.3.2.2 UK Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.2.3 Target Disease Prevalence
9.3.2.4 Competitive Scenario
9.3.2.5 Regulatory Framework
9.3.2.6 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.3.3 Target Disease Prevalence
9.3.3.4 Competitive Scenario
9.3.3.5 Regulatory Framework
9.3.3.6 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.4.3 Target Disease Prevalence
9.3.4.4 Competitive Scenario
9.3.4.5 Regulatory Framework
9.3.4.6 Reimbursement Scenario
9.3.5 Italy
9.3.5.1 Key Country Dynamics
9.3.5.2 Italy Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.5.3 Target Disease Prevalence
9.3.5.4 Competitive Scenario
9.3.5.5 Regulatory Framework
9.3.5.6 Reimbursement Scenario
9.3.6 Spain
9.3.6.1 Key Country Dynamics
9.3.6.2 Spain Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.6.3 Target Disease Prevalence
9.3.6.4 Competitive Scenario
9.3.6.5 Regulatory Framework
9.3.6.6 Reimbursement Scenario
9.3.7 Denmark
9.3.7.1 Key Country Dynamics
9.3.7.2 Denmark Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.7.3 Target Disease Prevalence
9.3.7.4 Competitive Scenario
9.3.7.5 Regulatory Framework
9.3.7.6 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.8.3 Target Disease Prevalence
9.3.8.4 Competitive Scenario
9.3.8.5 Regulatory Framework
9.3.8.6 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Norway Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.4 Asia Pacific
9.4.1 Asia Pacific Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.2.3 Target Disease Prevalence
9.4.2.4 Competitive Scenario
9.4.2.5 Regulatory Framework
9.4.2.6 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.3.3 Target Disease Prevalence
9.4.3.4 Competitive Scenario
9.4.3.5 Regulatory Framework
9.4.3.6 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.4.3 Target Disease Prevalence
9.4.4.4 Competitive Scenario
9.4.4.5 Regulatory Framework
9.4.4.6 Reimbursement Scenario
9.4.5 Australia
9.4.5.1 Key Country Dynamics
9.4.5.2 Australia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.5.3 Target Disease Prevalence
9.4.5.4 Competitive Scenario
9.4.5.5 Regulatory Framework
9.4.5.6 Reimbursement Scenario
9.4.6 South Korea
9.4.6.1 Key Country Dynamics
9.4.6.2 South Korea Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Thailand Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.5 Latin America
9.5.1 Latin America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.2.3 Target Disease Prevalence
9.5.2.4 Competitive Scenario
9.5.2.5 Regulatory Framework
9.5.2.6 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.3.3 Target Disease Prevalence
9.5.3.4 Competitive Scenario
9.5.3.5 Regulatory Framework
9.5.3.6 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.5.4.3 Target Disease Prevalence
9.5.4.4 Competitive Scenario
9.5.4.5 Regulatory Framework
9.5.4.6 Reimbursement Scenario
9.6 Middle East and Africa
9.6.1 Middle East and Africa Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
9.6.1.1 Target Disease Prevalence
9.6.1.2 Competitive Scenario
9.6.1.3 Regulatory Framework
9.6.1.4 Reimbursement Scenario
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.2.3 Target Disease Prevalence
9.6.2.4 Competitive Scenario
9.6.2.5 Regulatory Framework
9.6.2.6 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.3.3 Target Disease Prevalence
9.6.3.4 Competitive Scenario
9.6.3.5 Regulatory Framework
9.6.3.6 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.4.3 Target Disease Prevalence
9.6.4.4 Competitive Scenario
9.6.4.5 Regulatory Framework
9.6.4.6 Reimbursement Scenario
9.6.5 KUWAIT
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
9.6.5.3 Target Disease Prevalence
9.6.5.4 Competitive Scenario
9.6.5.5 Regulatory Framework
9.6.5.6 Reimbursement Scenario
Chapter 10 Competitive Landscape
10.1 Company Categorization
10.2 Participant’s Overview
10.3 Financial Performance
10.4 Product Benchmarking
10.5 Company Market Positioning
10.6 Company Market Share Analysis, 2022
10.7 Company Heat Map Analysis
10.8 Strategic Initiatives
10.9 Company Profiles
10.9.1 NOVO NORDISK A/S
10.9.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
10.9.3 F. HOFFMANN LA-ROCHE LTD.
10.9.4 BAYER AG
10.9.5 PFIZER, INC.
10.9.6 CSL BEHRING
10.9.7 BIOMARIN
10.9.8 OCTOPHARMA AG
10.9.9 SANOFI
10.9.10 SPARK THERAPEUTICS, INC.
List of Tables
TABLE 1 List of Abbreviation
TABLE 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
TABLE 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
TABLE 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 16 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
TABLE 17 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 18 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 19 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 20 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 21 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 22 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 23 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 24 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 25 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 26 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 27 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 28 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 29 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 30 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 31 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 32 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 33 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 34 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 35 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 36 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 37 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 38 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 39 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 40 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 41 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 42 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 43 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 44 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 45 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 46 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 47 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 48 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 49 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 50 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 51 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 52 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 53 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
TABLE 54 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 55 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 56 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 57 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 58 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 59 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 60 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 61 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 62 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 63 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 64 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 65 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 66 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 67 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 68 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 69 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 70 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 71 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 72 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 73 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 74 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 75 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 76 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 77 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 78 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 79 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 80 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 81 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 82 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
TABLE 83 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 84 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 85 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 86 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 87 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 88 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 89 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 90 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
TABLE 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 116 KUWAIT Hemophilia Market, By Type, 2018 - 2030 (USD Million)
TABLE 117 KUWAIT Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
TABLE 118 KUWAIT Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
TABLE 119 KUWAIT Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global hemophilia market- Key market driver analysis
FIG. 7 Global hemophilia market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global hemophilia market - Porter’s analysis
FIG. 10 Global hemophilia market - PESTEL analysis
FIG. 11 Global hemophilia market type outlook key takeaways
FIG. 12 Global hemophilia market: Type movement analysis
FIG. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
FIG. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
FIG. 15 Others market estimates, 2018 - 2030 (USD Million)
FIG. 16 Global hemophilia market treatment outlook key takeaways
FIG. 17 Global hemophilia market: Treatment Type movement analysis
FIG. 18 On-demand market estimates, 2018 - 2030 (USD Million)
FIG. 19 Cure market estimates, 2018 - 2030 (USD Million)
FIG. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
FIG. 21 Global hemophilia market therapy outlook key takeaways
FIG. 22 Global hemophilia market: Therapy movement analysis
FIG. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
FIG. 24 Desmopressin & Fibrin Sealants market estimates, 2018 - 2030 (USD Million)
FIG. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
FIG. 26 Regional marketplace: Key takeaways
FIG. 27 Global hemophilia market: Regional movement analysis
FIG. 28 North America hemophilia market, 2018 - 2030 (USD Million)
FIG. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
FIG. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
FIG. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
FIG. 32 UK hemophilia market, 2018 - 2030 (USD Million)
FIG. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
FIG. 34 France hemophilia market, 2018 - 2030 (USD Million)
FIG. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
FIG. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
FIG. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
FIG. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
FIG. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
FIG. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
FIG. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
FIG. 42 China hemophilia market, 2018 - 2030 (USD Million)
FIG. 43 India hemophilia market, 2018 - 2030 (USD Million)
FIG. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
FIG. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
FIG. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
FIG. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
FIG. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
FIG. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
FIG. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
FIG. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
FIG. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
FIG. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
FIG. 54 UAE market, 2018 - 2030 (USD Million)
FIG. 55 Kuwait market, 2018 - 2030 (USD Million)
FIG. 56 Strategy framework

Companies Mentioned

  • NOVO NORDISK A/S
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • F. HOFFMANN LA-ROCHE LTD.
  • BAYER AG
  • PFIZER, INC.
  • CSL BEHRING
  • BIOMARIN
  • OCTOPHARMA AG
  • SANOFI
  • SPARK THERAPEUTICS, INC.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages105
PublishedJuly 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 12.6 billion
Forecasted Market Value ( USD ) by 2030 $ 21.07 billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 120 Pages
  • Global
From
Global Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Forecast 2024-2030 - Product Image

Global Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Forecast 2024-2030

  • Report
  • 191 Pages
  • Global
From
Hemophilia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Hemophilia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Hemophilia Drugs Market Analysis & Forecast 2024-2034: Market By Type; By Treatment; By Therapy; By End-user; and By Region - Product Image

Global Hemophilia Drugs Market Analysis & Forecast 2024-2034: Market By Type; By Treatment; By Therapy; By End-user; and By Region

  • Report
  • 145 Pages
  • Global
From
Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028) - Product Image

Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)

  • Report
  • 102 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.